Hengrui Pharma(SH:600276) 智通财经网·2025-11-17 08:31Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of HRS-6209 capsules and HRS-2189 tablets, targeting breast cancer treatment [1] Group 1: Product Development - HRS-6209 is a novel selective CDK4 inhibitor that effectively inhibits the CDK4/cyclinD complex and downstream signals, inducing tumor cell arrest in the G1 phase, aimed at treating advanced malignant solid tumors [1] - HRS-6209 has improved selectivity for the CDK6/cyclinD3 signaling pathway compared to CDK4/6 inhibitors, potentially reducing blood toxicity associated with CDK4/6 inhibitors [1] - The total R&D investment for HRS-6209 has reached approximately 80.37 million yuan [1] Group 2: Market Position - There are currently no similar products approved for market in both domestic and international markets for HRS-6209 [1] - HRS-2189 is a new KAT6 inhibitor that regulates downstream oncogene expression by inhibiting histone lysine acetylation, also aimed at treating advanced malignant tumors [1] - The total R&D investment for HRS-2189 has reached approximately 49 million yuan [1] - There are currently no approved drugs targeting the same pathway as HRS-2189 in both domestic and international markets [1]